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Introduction: The burden of disease attributable to tobacco use in Latin America is very 
high. Our objective was to evaluate the 10-year potential impact of current legislation related 
to cigarette packaging and warnings and expected effects of moving to a higher level of 
strategies implementing cigarette plain packaging on health and cost outcomes in Argentina, 
Bolivia, Brazil, Chile, Colombia, Mexico, and Peru, using a microsimulation model. 
  
Methods: We used a probabilistic state-transition microsimulation model, considering 
natural history, costs and quality of life losses associated with main tobacco-related diseases. 
We followed up individuals in hypothetical cohorts and calculated health outcomes annually 
to obtain aggregated long-term population health outcomes and costs. We performed a 
literature review to estimate effects. and analysed studies and information from ministries, 
relevant organizations, and national surveys. We calibrated the model comparing the 
predicted disease specific mortality rates with local statistics.  
  
Results: Current graphic warnings already in place in each country could avert, over 10 
years, 69,369 deaths and 638,295 disease events, adding 1.2 million years of healthy life and 
saving USD 5.3 billion in the seven countries. If these countries implemented plain 
packaging strategies, additional 155,857 premature deaths and 4,133,858 events could be 
averted, adding 4.1 million healthy years of life and saving USD 13.6 billion in direct 
healthcare expenses of diseases attributable to smoking.  
 
Conclusion: Latin American countries should not delay the implementation of this strategy 
that will alleviate part of the enormous health and financial burden that tobacco poses on their 






















Tobacco smoking is the single most preventable and premature mortality cause in the world. 
The Framework Convention on Tobacco Control, supported by the World Health 
Organization, introduced a package of evidence-based measures for tobacco control. This 
study adds evidence on the potential health effects and savings of implementing cigarette 
plain packaging in countries representing almost 80% of Latin American population; findings 
























Tobacco smoking is the single most preventable, premature mortality cause in the world, with 
about six million deaths every year.
1,2
 Globally, the amount of healthcare expenditure for 
smoking-attributable diseases surpasses USD 400 billion, and the economic cost of smoking 
represents USD 1,436 billion; about 40% of this cost corresponds to low- and middle-income 
countries.
3
 In Latin America, the annual consumption of tobacco per person is estimated 160 
to 2,000 cigarettes with a prevalence between 6.4% and 35.2%.
4
   
  
Due to the increasing smoking-related health costs and the high toll of smoking-attributable 
diseases, several interventions to counter chronic diseases’ risk factors have been prioritised 
as “best buys” by World Health Organization (WHO), meaning they could favourably and 
efficiently improve population health.
5,6
 In 2007, WHO promoted the Framework Convention 
on Tobacco Control (FCTC) that included six evidence-based measures, referred as 
MPOWER for its acronyms; measures were Monitoring tobacco use and tobacco control 
measures; Protecting people from tobacco smoke; Offering help to quit tobacco; Warning 
people about the dangers of tobacco; Enforcing bans on tobacco advertising, promotion and 
sponsorship; and Raising tobacco taxes.
7
 Although many MPOWER strategies have been 
implemented in various countries, with almost 3 billion people now covered by at least one 
measure at its highest level of achievement, their application in Latin America has 
encountered several barriers as a result of the heterogeneity in target populations and public 
health policies in the region, as well as to tobacco industry interference through aggressive 





The concept of plain packaging (sometimes referred to as standardized packaging) is defined  
as those “measures to restrict or prohibit the use of logos, colours, brand images or 
promotional information on packaging other than brand names and product names displayed 
in a standard colour and font style (plain packaging)”.
9,10
 Plain packaging pursues reducing 
the attractiveness of tobacco products, eliminating the effects of tobacco packaging as a form 























Health warnings and messages on tobacco product packaging and labelling may be in the 
form of or include pictures or pictograms. Article 11 of FCTC on "Packaging and labelling of 
Tobacco Products" stipulates that each packet and package of tobacco products and any 
outside packaging and labelling of such products carry health warnings describing the 
harmful effects of tobacco use, with other appropriate messages; such warnings shall be 
approved by the competent national authority, shall be rotating, shall be large, clear, visible 
and legible, should be 50% or more of the principal display areas but shall be no less than 
30% of the principal display areas, and may be in the form of or include pictures or 
pictograms. Evidence shows that health warnings and messages that contain both pictures and 
text are far more effective than those that are text-only.
12
 They also have the added benefit of 
potentially reaching people with low levels of literacy and those who cannot read the 
language(s) in which the text of the health warning or message is written.
9,10,13-15 
 
Australia was the first country to implement plain packaging in 2012, followed by France in 
2016, the UK and Ireland in 2017, Hungary, New Zealand, and Norway in 2018; Thailand 
and Uruguay in 2019, while other countries such as Canada, Singapore, Belgium, Romania, 
Turkey, Finland, Chile and South Africa have taken steps towards the introduction of this 
measure.
16
 An increasing number of Latin American countries have been adopting MPOWER 
measures with dissimilar results. Studies on the potential effects of implementing measures 
and on the level of current implementation through modelling are crucial for policy makers. 
Uruguay has been the first country in Latin America to adopt the plain packaging strategy.
16
 
In Latin America, hurdles to policy change still exist, with persisting knowledge gaps in 
many aspects; however, researchers have been working to produce local high-quality 
information in conjunction with policy makers.
17
 Hence, our model was designed to provide 
evidence on the health and financial burden of smoking in the region and cost-effectiveness 
of interventions to curb the tobacco epidemic.
18
 Of the countries studied, only Colombia 
currently has a level of implementation of health warnings that cover between 30% and 49% 



















to 80% of the pack. In 2009, Uruguay introduced legislation to increase the size of health 
warnings with significant subsequent increases in effectiveness indicators.
16,19 
 
The objective of this study is twofold: 1) to estimate the health and economic benefits that 
can be achieved through the current cigarette packaging policies in Argentina, Bolivia, 
Brazil, Chile, Colombia, Mexico, and Peru; and 2) to estimate the health and financial impact 
of improving current strategies through the implementation of cigarette plain packaging in 
these seven Latin American countries. 
 
METHODS 
The model used in this study is an individual-based Markov model (first-order Monte Carlo 
technique)
18 
that has been previously validated and applied in several studies to estimate the 
tobacco burden of disease, and the expected impact of tobacco tax increases and other 
tobacco control interventions
.20-24 
Through the model, the health and economic impact of 
tobacco under the present conditions in each country is estimated (status quo), and compared 
to hypothetical scenarios of reduced smoking prevalence as a consequence of the tobacco 
control interventions being evaluated (in the present paper we assess graphic warnings and 
plain packaging policies).  
The model considers the natural history, costs and quality of life losses associated with main 
tobacco-related diseases (coronary and non-coronary heart disease, cerebrovascular disease, 
chronic obstructive pulmonary disease, pneumonia, influenza, lung cancer and nine other 
neoplasms). Simulating each individual’s lifetime, we followed up individuals in hypothetical 
cohorts and calculated health outcomes on an annual basis to obtain aggregated long-term 
population health outcomes and costs. For acute events, we calculated age and gender-
specific absolute risks based on national mortality rates and the lethality of the event. Then, 
the baseline risk in non-smokers is calculated based on the smoking prevalence in each age 
and sex group, and the relative risk of smoking associated with each event. For cancers, we 




















The model updates input parameters for each subject in yearly cycles and calculates 
individual lifetime risks of occurrence of each event, disease progression and death, based on 
demographic attributes, smoking status, and clinical conditions based on the underlying risk 
equations. The main outcomes are life years, quality-adjusted life years, disease events, 
hospitalisations, disease incidence and disease costs. We calculated the years of life lost 
(YLL) due to smoking-related diseases at a population level as the sum of years of life lost 
due to premature death (PYLL); and years of life lost due to living with a poor quality of life 
(YLL-QL). As the model does not directly calculate the consequences of passive smoking 
and perinatal effects, based on the results of previous studies, we assumed that these causes 
impose an additional burden of 13.6% for men and 12% for women.
26 
Modeling of policy effect 
Tobacco control policies have an effect mediated by a reduction in consumption. This lower 
consumption at the country level is a consequence of both a reduction in the number of 
cigarettes smoked per smoker, and lower tobacco prevalence due to an increase in quitting 
rates (short term) and lower tobacco initiation rates in the medium and long term. To estimate 
the impact of implementing plain tobacco packaging, the smoking prevalence post-
intervention was calculated as:  
𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐epost = 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐epre − (𝐸𝑚 ∗ 𝐼𝑝 ∗ 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐epre) 
Where Prevalencepre is the prevalence of smokers before the intervention, Em is the 
effectiveness of the intervention expressed as relative reduction in tobacco consumption, and 
Ip it is the proportion of variation in consumption that impact smoker prevalence. Different 
studies have estimated that, in the short and medium term, approximately half of the 
reduction in consumption is a consequence of reduced prevalence and the other half is 





















Model scenarios  
To estimate the potential impact of tobacco control policies we analysed three scenarios in 
each country. 
1.     Short-term scenario: we assumed that a 50% of the reduction in consumption 
would have an impact on prevalence (Ip=0.5) and that the reduction in prevalence 
led to an increase in former smokers. This conservative scenario is more likely to 
occur in the short term, as it does not include effects that the intervention may 
have in preventing people from starting to smoke or the health benefits of 
smoking fewer cigarettes for those who continue smoking.  
2.     Mid-term scenario: similar to the previous scenario, but it also incorporates the 
potential effects associated with a reduction in the number of cigarettes smoked in 
continuing smokers. It is assumed that low-intensity smokers have in average 75% 
less excess disease risk than high-intensity smokers  (82% less for lung cancer, 
57% less for ischemic heart disease and 80% less for COPD)
32
, and consequently 
the reduction in the number of cigarettes smoked is modelled as a proportional reduction 
in the 75% of the excess risk difference between a smoker and a former-smoker. 
3.     Long-term scenario: maximum effect over ten years. Similar to the previous one, 
but here Ip = 0·75 and the entire reduction in prevalence results in an increased 
population of non-smokers,  
 
The base case consisted of comparing health benefits and costs of current packaging policy in 
each country to those predicted by implementing plain packaging. To estimate disease burden 
and costs of plain packaging strategy, we assumed a linear evolution from scenario 1 to 
scenario 2 within five years, and then to scenario 3 between years six to ten.  
The burden of disease attributable to smoking was estimated for these scenarios based on 
these estimates of changes in smoking prevalence and new proportions of smokers, former 
smokers and non-smokers. Health impact was calculated as the observed difference between 
baseline burden (status quo) and the plain packaging strategy estimates, in terms of deaths, 
disease events, years lived, disability, and health costs. More information about the model 
























Argentina, Bolivia, Brazil, Chile, Mexico and Peru currently have health warnings covering 
between 50% and 80% of pack surface, whereas Colombia has warnings covering 30-49% of 
the cigarette package,
7
 (Figure 1).  
  
Figure 1. Current implementation level of policies related to health warnings and 
plain packaging and estimated effect in prevalence reduction in seven countries in 
Latin America.   
  
Information sources for the model 
Epidemiological information 
To populate the simulation model, we obtained data through a review of the literature on 
MEDLINE, EMBASE, CENTRAL, SOCINDEX, EconLit, LILACS, NBER, CRD and Cost 
Effectiveness Analysis Registry, the International Tobacco Health Conference Paper Index 
and Cochrane Tobacco Addiction Review Group register. Also, we reviewed grey literature 
from ministries of health or of finance, Pan American Health Organisation, and regional 
congresses proceedings. We obtained updated information on tobacco use from tobacco 
GATS surveys and national risk factor surveys. Researchers from participating countries 
provided information from civil registrations, vital statistics and hospital discharge databases 






















We performed a literature search to identify reported costs of events and developed a 
common costing methodology to estimate costs through a micro costing or macro costing 
approach, depending on the information availability. Then, we used a spreadsheet for each 
event, with frequency, use rate and unit cost of health resources. We constructed ad hoc 
micro costing exercises, based on experts’ opinions, clinical guidelines and a review of 
healthcare facility records. The costs of malignancies other than lung cancer were based on 
cost of each cancer relative to lung cancer costs and consensus using a Delphi method 
exercise with oncology experts from studied countries. Where local information was 
unavailable, we extrapolated the model to approximate costs of events. In those cases, we 
used the average proportion that represents event cost divided by per capita GDP in 
Argentina, Chile and Mexico; then, on this average proportion, the per capita GDP of the 
country of interest was applied to obtain estimates.  
  
All costs were first estimated in the local currency; then, consumer price indices, published 
by the statistics institutes of each country, were used for cost adjustments and finally, costs 
were converted to US dollars using the exchange rates published by each country’s central 
bank. Exchange rates used were average value in 2015, as follows USD 1.00 was Argentina 
ARS 9.27, Bolivia BOB 6.91, Brazil BRL 3.34, Chile CLP 654.07, Colombia COP 2743.39, 
Mexico MXN 15.84, Peru PEN 3.18.  
  
Estimation for intervention impact 
To obtain data on the benefits of implementing health warnings and the plain packaging of 
tobacco products to populate the simulation model, we performed a three-stage systematic 
review. First, we performed a review of documents published by relevant international 
organizations, then an overview of systematic reviews on the effectiveness of graphic 
warnings and plain packaging interventions at the global level, and, finally a systematic 
review of this specific intervention in the seven Latin American countries included in this 
study (Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru). See supplemental file 



















base, agreed upon by the group of authors. A sensitivity analysis with the extreme values of 
the range of effectiveness reported in the literature was additionally performed. 
  
Calibration and validation of the model 
We applied the International Society for Pharmacoeconomics and Outcomes Research criteria 
for model development and reporting
 
to calibrate the model in each country, compared 
mortality rates predicted by the model with the national statistics for 16 conditions (excluding 
COPD mortality, which is widely underestimated in national statistics).
33
 Sex- and age-
specific model outputs were compared to the source and deviations from the expected values 
were analysed. Predicted rates were accepted if within 10% of references. In case of greater 
deviation, risk equations were modified until the parameter was within an acceptable range. 
Goodness of fit was assessed by plotting predicted versus observed values outcomes, fitting a 
linear curve through the points with the intercept set at zero, and obtaining a squared linear 
correlation coefficient. We externally validated the model comparing results of other 
epidemiological and clinical studies not used in our model.  
  
RESULTS 
Data to populate the model 
We identified all the epidemiological and cost parameters needed to populate the model and 
show the main results of input parameters in Table 1. The systematic review on the 
effectiveness of health warnings showed that smoking prevalence could be reduced by 0.6% 
if non-graphic warnings covered less than one third of the pack, by 3% if they covered at 
least one third of the pack, and by 6% if they covered at least 50% of the pack. Due to the 
limited experience worldwide, there is greater uncertainty regarding the potential effect of 
implementing plain packaging. Available data indicate that this effect could be between an 
additional 3.15% to 15.2%.
19,34-36
 For the base case, we assumed that plain packaging would 
reach a relative reduction equivalent to the decrease achieved when moving from non-graphic 
warnings covering at least one third of the pack to graphic warnings covering at least 50% of 




















Model calibration and validation 
After the calibration process was completed, the average rate of each predicted event was 
within 10% of the rate reported by national statistics (correlation between observed and 
expected results yielded R
2
 values ranging from 0.700 to 0.999). External validation also 
showed a good correlation between predicted results and those in epidemiology studies. 
Supplementary material shows calibration and validation process in Argentina. 
Health and economic benefits of current strategies  
The health warnings policies that are currently in place in these seven countries (Figure 1), if 
properly applied and maintained, are already producing health and economic benefits thanks 
to their potential to avert a total of 69,369 deaths, 167,251 cardiac diseases, 47,768 
cerebrovascular diseases, 86,776 COPD, and 305,836 cases of cancer, totalling 638,295 
disease events, over a period of 10 years; which could add 1.2 million years of healthy life 
and save USD 5.3 billion in direct medical costs.  
  
In Brazil, the country with the largest population in the group, 34,121 deaths and 223,585 
events could be averted, with over 1 million healthy years lived, and USD 2.4 billion in 
savings. In number of averted deaths, Argentina and Mexico come in second and third places, 
with 11,024 and 10,229, respectively. Moreover, Mexico could prevent 316,077 events 
followed by Argentina, with 44,710 events (Table 2).  
  
Potential impact of implementing a plain packaging strategy 
So far, the studied countries have not implemented plain tobacco packaging. If the seven 
countries moved to health warnings of more than 80% of the pack and plain packaging, 
155,857 premature deaths would be averted (range: 118,177 to 277,898) over a ten-year 
period. The implementation of this measure would also avoid 437,198 cardiac events (range: 
331,267 to 780,290); 132,116 cerebrovascular events (range: 99,810 to 236,753); 117,283 
COPD (range: 88,344 to 211,019), and 597,501 cancer diagnosis (range: 455,338 to 
1,057,912); totalling 4,133,858 potentially avoidable disease events. A total of 4.1 million 



















direct healthcare expenses of diseases attributable to smoking (range: 10.1 to 24.6) would be 
saved (Table 3) in the next ten years. In absolute values, Brazil leads in the number of deaths 
that could be avoided in plain packaging is implemented (120,730 deaths) followed by 
Argentina, with 39,007, and Mexico, with 36,193 averted deaths.  
DISCUSSION 
Our results show that the graphic health warning policies currently in place in these seven 
Latin American countries (Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru) are 
already producing non-negligible health and economic benefits; 69,369 averted deaths and 
USD 5.3 billions saved in direct medical costs every 10 years. However, these countries are 
missing the opportunity to obtain much greater benefits. If plain packaging plus graphic 
health warnings covering at least 80% of the pack were implemented, this strategy would 
increase the number of averted smoking-associated deaths by 224%, to 155,857. For the 
seven countries, the number of averted health events would increase by 218%, to 1.4 million, 
and savings in direct costs to the health system would increase by 258%, reaching US$ 19.4 
billion. Of note, these countries represent almost 80% of the population of Latin America.  
We observed wide differences among countries regarding absolute values, mostly because of 
variations in total population (i.e. 207.8 million in Brazil and 10.7 million Bolivia) and in the 
prevalence of tobacco use, ranging from 6.4% in Mexican women to 35.2% in Chilean men. 
Colombia currently has the lowest level of warnings, for this reason the country would obtain 
extra benefits in relative terms from transitioning to plain packaging. Although the estimated 
health and economic benefits of moving to plain packaging varied widely among the 
analysed countries, these are still very high in the seven countries.  
There is no single strategy capable to address the tobacco epidemic; and plain packaging 
should be used along with other evidenced-based measures such as increased taxation, 
product regulation, and others.
37
 However, with at least one MPOWER policy at its highest 
level of implementation, 88 countries averted 22 million premature deaths, and the three most 
effective strategies were taxes increase, comprehensive smoke-free laws and graphic health 
warnings.
38
 One of the strategies actively endorsed by WHO is the increase in taxes to 
tobacco products. In other studies, we estimated that higher benefits could be gained with a 
50% price increase in tobacco through a raise of taxes compared with plain packaging. For 



















avoid 136,482 deaths, 507,451 cases of cardiovascular diseases, 64,382 cases of cancer, and 
100,365 cases of stroke and the estimated economic benefit would be USD 25.5 billion in the 
next ten years; representing twice the expected benefit of plain packaging.
21
 We also 
estimated that if these seven countries fully implemented smoke-free air strategies, it would 
be possible to avert nearly 180,000 premature deaths and 1,2 million events, adding 5 million 
healthy years of life and saving USD 13.1 billion in direct healthcare costs. Our data show the 
expected benefits of the implementation of plain packaging would be significant even in the 
most conservative scenarios, and the effects achieved through the adoption of graphic and 
large health warnings over the last years could be further increased by adopting plain 
packaging. 
In the Latin American region, only two observational studies assessed the decision to quit 
smoking after the implementation of warnings in Mexico and Uruguay.
19,35
 Tobacco Free 
Kids reported that in Brazil, health warnings led to 67% of surveyed smokers reporting their 
intention to stop smoking.
16
 Moreover, two systematic reviews of the effects of warnings on 
smoking prevalence showed inconclusive evidence and a high heterogeneity on the definition 
of reduction of consumption, measurement of exposure, study design, population, and 
statistical analysis.
34,41
 Reports such as Tobacco Atlas have shown that in Australia, smoking 
prevalence diminished after the implementation of plain packaging.
8,42 
 
Levy et al estimated the effects of implementing graphic warnings in the United States, where 
only small and text-only labels on one side of the cigarette pack are required,  and showed 
that smoking prevalence would be reduced by 5% in the first few years, and 10% in the long-
term through the effects on initiation and cessation.
12
 Although these figures are consistent 
with the scenarios explored in our analysis (3.15% to 15.2%), Levy et al did not include plain 
packaging in their model.
12 
In our systematic review, we only found one study addressing the 
effectiveness of plain packaging; it was performed in Australia, where the tobacco prevalence 
has been decreasing as a result of the implementation of several strategies. Due to the 
uncertainty in how to extrapolate this result to Latin-America, we reached a consensus with 
experts and decided that the effectiveness in our region could be like that assumed with the 





















The tobacco industry and other opponents of health warnings and plain packaging measures 
argue that these strategies will increase counterfeit and illicit tobacco purchasing or decrease 
revenues; the industry has challenged the measures adopted in Australia and Uruguay 
adducing breaches of international trade agreements and intellectual property legislation.
43
 
Another strategy used by the tobacco industry to respond to these initiatives was the 
introduction of new products, extended brands or pack sizes options.
44,45
 Evidence suggests 
that plain packaging does not increase retail transaction times or the use of illicit or 
counterfeit tobacco; importantly, the decisions on legal cases may depend on the evidence 
indicating health benefits outweighing the manufacturers’ interests.
43
 Our study, in 
accordance with previous research on the effects of other measures, shows that taking this 




Our study has important limitations that should be considered. The main limitation is the 
scarcity of high-quality evidence addressing the effectiveness of plain packaging 
implementation. For this reason, a conservative base case scenario was assumed, and 
parameter uncertainty was addressed through sensitivity analysis. Some conditions that could 
be related to smoking such as kidney failure, breast cancer or diabetes were not included, and 
indirect costs were not assessed. Despite having a negligible effect, this could underestimate 
the burden of smoking-related diseases and the benefits of the interventions. We have been 
conservative about the benefits of a reduction in consumption not mediated by quitting, 
although this remains controversial. Also, we did not include the effects of tobacco products 
other than cigarettes and did not differentiate the effects of graphic warnings and plain 
packaging on the quantity smoked, smoking cessation and initiation. However, this limitation 
closely mimicks real-world scenarios as plain packaging policy and enlarged graphic 
warnings were introduced simultaneously.
39 
Moreover, the effects depend on the projections 
of smoking prevalence. The model relies on data provided by official institutions of the 
participating countries; therefore, potential inaccuracies and the lack of good-quality 
epidemiological and cost information in the region represent a threat. The relative risks used 
in our model are based on studies from other countries and could vary in Latin America. 
Despite these limitations, given the large number of countries and medical conditions 
included, our results offer a robust estimate of the benefits of implementing plain packaging 




















In summary, the graphic health warning policies currently in place are producing non-
negligible health and economic benefits. However, our study shows that these seven countries 
could still significantly improve population health and reduce healthcare costs through the 
implementation of a plain packaging strategy. Latin American countries should not delay this 
decision which would substantially alleviate the enormous health and financial burden that 
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Table 1. Main inputs for the simulation model. 
















Smoking prevalence1        
 Male 23.4 20.1 18.0 35.2 20.1 19.8 23.5 
 Female 18.6 17.7 11.3 31.3 9.9 6.4 15.3 
Crude mortality rate (Male / Female per 10,000)
2
 
Acute myocardial infarction  46.1 / 
33.1 











0.9 / 0.5 3.8 / 2.9 7.4 / 
8.4 
2.3 / 1.7 2.2 / 3.1 51.8 / 57.2 
Cerebrovascular disease 52.5 / 
43.9 
8.4 / 8.0 8.8 / 7.9 9.8 / 
9.6 
8.5 / 9.3 8.1 / 8.1 52.6 / 50.7 




9.1 / 8.5 4.2 / 
4.0 
3.6 / 3.1  4.0/ 3.1 221.0/199.
0 
COPD 4.3 / 1.9 1.1 / 1.3 6.6 / 4.5 3.7 / 
2.8 
7.9 / 5.8 7.5 / 5.6 33.2 / 25.3 
Lung cancer  15.6 / 4.6 3.7 / 3.1 4.3 / 2.5 3.9 / 
2.2 
3.3 / 1.9 2.5 / 1.2 13.5 / 10.4 
Estimated direct health costs of smoking-related conditions in USD millions     
Acute myocardial 
infarction 
3,242 5,114 5,006 3,944 3,835 4,848.6 2,663 
Other cardiovascular 
causes  
2,432 3,835 1,881 2,702 1,534 3,190.4 1,850 
Annual cardiovascular 
follow-up.  





4,294 5,232 4,304 4,431 2,174 4,119.1 5,058 
Pneumonia 
/influenza 
217 276 361 235 325 1,309.9 174 
COPD
4
 4,394 3,969 4,824 6133 3,463 9,236.2 4,363 
Lung cancer
5
 17,392 8,862 12,279 21,727 10,499 13,792.6 14,081 
Mouth cancer
5
 12,523 6,381 9,602 15,644 7,560 9,930.6 9,251 
Oesophageal cancer  14,610 7,444 12,161 18,251 8,820 11,585.7 11,828 
Stomach cancer
5
























 11,827 6,026 11,616 14,774 7,140 9,378.9 9,575 
Kidney cancer
5
 12,523 6,381 4,632 15,644 7,560 9,930.6 10,138 
Tax revenue on smoking
6















GDP per capita (2015)
6 
13,432 3,095 8,539 13,384 6,056 9,009 6,122 
Price elasticity of demand  -0.299 -0.85 -0.48 -0.45 -0.780 -0.45 -0.7 
Total health expenditure 
(% GDP) 
4.8 6.3 8.3 7.8 7.2 6.3 5.5 
Abbreviations: GDP, gross domestic product; COPD, chronic obstructive pulmonary disease. Key: 1. Population ≥35 years 
expressed in millions; 2. Mortality rate per 10.000 people; 3. Values include first and following years, as a summary, only 
first year is included in table. 4. COPD mild, moderate and serious included. 5. Treatment costs of following years are 

























































COPD Cancer Total events 
Argentina 11,024 17,460 6,326 15,830 5,094 44,710 265,013 $906  
Bolivia 1,534 894 1,688 2,444 443 5,469 39,397 $92.5  
Brazil 34,121 126,863 25,091 55,535 16,096 223,585 1,019,088 $2,400  
Chile 5,467 6,878 6,399 12,433 2,206 27,916 143,120 $545  
Colombia 3,465 10,936 4,844 5,657 1,339 22,776 90,285 $196.4  
Mexico 10,229 26,418 6,430 3,845 279,384 316,077 279,384 $934.5  
Peru 3,529 2,140 3,316 6,862 1,274 13,592 86,598 $183  



























Table 3. Ten-year Cumulative benefits to be obtained by implementing plain packaging 





deaths          
N (range) 
Averted events                                     
Base case (range) 
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